BioCentury
ARTICLE | Company News

Cipla, Meda sales and marketing update

June 10, 2013 7:00 AM UTC

Cipla and Meda added full rights in Latin and South America, the Middle East, Africa and Asia to 2008 and 2009 deals granting Meda exclusive rights to develop and commercialize Cipla's Dymista azelastine/fluticasone in North America, Europe, Japan, Brazil, South Korea and Australia. Cipla will be responsible for formulation, and Media will be responsible for clinical development, regulatory approval and commercialization. Cipla will receive an upfront payment and is eligible for milestones. The companies declined to provide details (see BioCentury, Sept. 14, 2009). ...